Clinical Trial Detail

NCT ID NCT03554044
Title Talimogene Laherparepvec With Paclitaxel or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors University of California, San Francisco
Indications

Her2-receptor negative breast cancer

Therapies

Letrozole + Talimogene laherparepvec

Talimogene laherparepvec + Tamoxifen

Exemestane + Talimogene laherparepvec

Fulvestrant + Talimogene laherparepvec

Anastrozole + Talimogene laherparepvec

Paclitaxel + Talimogene laherparepvec

Age Groups: adult senior

Additional content available in CKB BOOST